廣譽遠(600771.SH):向公司全體股東贈送公司產品並提供接待參觀服務
格隆匯6月7日丨廣譽遠(600771.SH)公佈,為便於股東更好地瞭解公司並體驗公司產品,公司決定以免費方式向全體股東贈送公司藥食同源類健康產品,並提供中醫藥文化產業園定期接待參觀和全國部分博物館免費接待參觀服務,現將活動內容公吿如下:
2024年6月21日(公司2023年年度股東大會股權登記日)15:00收市後在中國證券登記結算有限責任公司上海分公司登記在冊的持有公司股份的股東。申領時間為2024年6月24日08:00至2024年7月1日17:00。在申領時間內未進行本次活動申領登記的,則視為股東自動放棄參與本次活動的權利。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.